
1. recent pat inflamm allergy drug discov. 2014;8(2):85-91.

an overview hepatitis c vaccines.

garcia a, fernandez s, toro f, de sanctis jb(1).

author information: 
(1)instituto de inmunolog√≠a, facultad de medicina, universidad central de
venezuela, apartado 50109, caracas 1050-a, venezuela. alexisgarcia27@gmail.com.

the hepatitis c virus (hcv) prevalent human pathogen causes persistent 
liver infections infected individuals; thus, efforts develop safe
vaccine, preventive therapeutic, urgently needed. current approaches 
the vaccine include use recombinant e1 e2 proteins, synthetic
peptides, viral particles, viral vectors, dna vaccines, dendritic cells, and
prime-boost strategies. however, several problems encountered:
restricted humoral cell mediated responses, low delivery potentially
protective viral epitopes, low effectiveness adjuvants used the
different protocols. strong neutralizing antibodies powerful cellular immune 
responses required effective vaccine hcv. new patents are
being developed enhance immune responses. high prevalence global
hcv infection obliges development new efforts primary prevention;
therefore, safe efficient vaccine confer protection hcv is
urgently needed.

doi: 10.2174/1872213x08666140704115149 
pmid: 25000932  [indexed medline]

